Molecular structure of K 858, CAS Number: 72926-24-0
K 858 (CAS 72926-24-0)
Application:
K 858 is a selective ATP-uncompetitive mitotic kinesin Eg5 inhibitor
CAS Number:
72926-24-0
Purity:
≥99%
Molecular Weight:
277.34
Molecular Formula:
C13H15N3O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics. Studies on HCT116 cells indicate that K 858 causes mitotic arrest, cell growth inhibition, and activates caspase-3. It is also believed that K858 inhibits the growth of cancer cells. Studies suggest that K 858 is not neurotoxic in motor coordination. Furthermore, K 858 can be a beneficial tool because unlike similar compounds that inhibit Eg5, K 858 does not form breaks in double stranded DNA.
K 858 (CAS 72926-24-0) References
- K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. | Nakai, R., et al. 2009. Cancer Res. 69: 3901-9. PMID: 19351824
- STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity. | Indorato, RL., et al. 2013. Biochem Pharmacol. 86: 1441-51. PMID: 24041742
- Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma. | De Monte, C., et al. 2015. Eur J Med Chem. 105: 245-62. PMID: 26498571
- The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells. | De Iuliis, F., et al. 2016. Invest New Drugs. 34: 399-406. PMID: 26994617
- The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells. | Taglieri, L., et al. 2018. Invest New Drugs. 36: 28-35. PMID: 28965307
- Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1,3,4-thiadiazoline analogue in tumor cells. | Giantulli, S., et al. 2018. Anticancer Drugs. 29: 674-681. PMID: 29738338
- Kinesin Eg5 Targeting Inhibitors as a New Strategy for Gastric Adenocarcinoma Treatment. | Marconi, GD., et al. 2019. Molecules. 24: PMID: 31683688
- Negative Modulation of the Angiogenic Cascade Induced by Allosteric Kinesin Eg5 Inhibitors in a Gastric Adenocarcinoma In Vitro Model. | Ricci, A., et al. 2022. Molecules. 27: PMID: 35164221
- The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells. | Nicolai, A., et al. 2022. Invest New Drugs. 40: 556-564. PMID: 35312942
- Kinesin Eg5 Selective Inhibition by Newly Synthesized Molecules as an Alternative Approach to Counteract Breast Cancer Progression: An In Vitro Study. | Ricci, A., et al. 2022. Biology (Basel). 11: PMID: 36290354
Inhibitor of:
Eg5, and Kinesin.Activator of:
caspase-3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
K 858, 10 mg | sc-300856 | 10 mg | $159.00 | |||
K 858, 50 mg | sc-300856A | 50 mg | $693.00 |